English
Language31 languages
EnglishEnglishDeutschGermanالعربيةArabicFrançaisFrenchEspañolSpanishPortuguês (Brasil)Brazilian PortugueseItalianoItalian日本語Japanese한국어KoreanРусскийRussianTürkçeTurkishفارسیPersian (Farsi)עבריתHebrewҚазақшаKazakhPolskiPolishNederlandsDutchRomânăRomanianČeštinaCzechΕλληνικάGreekMagyarHungarianBahasa IndonesiaIndonesianहिन्दीHindiاردوUrduBahasa MelayuMalayไทยThaiУкраїнськаUkrainianO‘zbekchaUzbekTiếng ViệtVietnamese繁體中文Traditional ChineseDanskDanishSvenskaSwedish

Supported languages are prioritized from the country mix of past inquiries. If you would like another language, please send us feedback.

Recent Confirmed OrdersLast 7 days
Australia2 gTirzepatide 100 mg · CagriSema 20 mg · BPC-157 10 mg · TB-500 5 mg · Melanotan II 10 mg · PT-141 10 mg · Bacteriostatic Water 3 ml
View all

Repair and regenerative research

BPC-157

Synthetic gastric pentadecapeptide research reference · preclinical evidence predominates

≥ 99.0% · target, verify batch COACAS 137525-51-0RUO
Research statusPreclinical-dominant evidence; extremely limited uncontrolled human safety report; no approved use reference context · supplied material is RUO
Supplied formLinear 15-residue peptide; free-base and acetate forms require separate specification
Lead time7–14 days
BPC-157 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA
BPC-157 — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA · Representative packaging image · verify the ordered lot
Representative packaging image · verify the ordered lot

Decision summary

Key benefits

  • Research applications include peptide identity and metabolism, gastric and intestinal injury models, tendon/ligament and other tissue-repair models, angiogenesis and nitric-oxide-related readouts, inflammation models and preclinical neural-injury research
  • Relative publication volume does not establish human therapeutic benefit.
Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS
137525-51-0
Formula
C62H98N16O22
Molecular weight
Approximately 1419.5 Da
Appearance
Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-batch COA
Purity
≥ 99.0% · target, verify batch COA
Storage
Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact free-base or acetate form. Do not assign a universal frozen shelf life or 28-day solution period.
MOQ
On request
Lead time
7–14 days
PubChem CID 9941957

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about BPC-157

BPC-157 is a synthetic linear 15-residue peptide, GEPPPGKPADDAGLV, associated with the “stable gastric pentadecapeptide” research literature. Most evidence is preclinical and includes gastrointestinal-injury, tissue-repair, inflammatory and nervous-system animal models. PubChem also links the name to an investigational record, but BPC-157 is not an approved finished medicine. A 2025 uncontrolled report in 2 healthy adults is far too small to establish human efficacy, dose or long-term safety. As of 15 July 2026, FDA has scheduled BPC-157 free base and acetate for 503A Bulks List advisory discussion on 23 July 2026; a scheduled non-binding review is not approval. The 2026 WADA list prohibits BPC-157 under S0.

  • Laboratory topics include gastrointestinal cytoprotection models, tissue-repair and angiogenesis models, inflammatory signaling, peptide metabolism and preclinical nervous-system injury
  • These are research applications, not approved indications or graded human efficacy claims.

Mechanism context

The question the literature is testing

Animal and cell studies propose effects involving angiogenesis, nitric-oxide signaling, endothelial pathways, growth-factor expression and cytoprotection. No single validated molecular receptor or target explains all reported findings, and route- or injury-site claims are not established in humans. Mechanistic studies require direct target, pathway and orthogonal comparator controls.

Evidence map

Research routes and exposure context

Evidence tierApproved finished-product context
Routes reported in sources
Intravenous
Dose / exposure contextProtocol-specific; verify the cited primary source
Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

  • Not approved for human or veterinary use
  • Animal toxicology and a 2-person uncontrolled human report cannot establish broad safety, contraindications, reproductive risk, adverse-event frequency or long-term outcomes
  • FDA review materials and the pending advisory process highlight the need for rigorous identity, impurity, aggregation and immunogenicity assessment
  • WADA prohibits BPC-157 under S0 for covered athletes
  • Laboratory work should follow the lot SDS and institutional controls; this catalogue provides no injection, anticoagulant, pregnancy or monitoring advice.

Interactions reported in the literature

  • No controlled evidence establishes synergy or compatibility with TB-500, growth-hormone-axis peptides, GLP-1/GIP medicines, copper peptides or other materials
  • Any co-formulation requires blend-specific analytical, stability, uniformity and compatibility development; theoretical pathway complementarity is not a recommendation.
Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

BPC-157 factory batch COAs

BPC-157 2 mg Factory batch COA protected previewBPC-1572 mg · WHJLP-BC2-260623-D
BPC-157 5 mg Factory batch COA protected previewBPC-1575 mg · WHJLP-BC5-260623-D
BPC-157 10 mg Factory batch COA protected previewBPC-15710 mg · WHJLP-BC10-260622-D
Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

  • Specify free base or acetate, complete 15-residue sequence, termini, counterion, formula and molecular-weight basis
  • Require lot traceability, theoretical and high-resolution observed intact mass, sequence-level evidence where appropriate, a stability-indicating chromatographic purity and impurity profile, quantitative peptide content, water, counterion and residual solvents, aggregation assessment where relevant and lot-specific stability
  • Sterility, endotoxin and bioburden are separate released-lot claims
  • Appearance or HPLC area alone cannot establish identity, content or human suitability.
Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack
BPC-02MG2 mg10 vials
BPC-05MG5 mg10 vials
BPC-10MG10 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released lot COA, SDS and formulation-specific stability statement. Temperature, light protection, shipping range, buffer, concentration, container and any post-reconstitution hold time require stability-indicating evidence for the exact free-base or acetate form. Do not assign a universal frozen shelf life or 28-day solution period.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls
These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

  • Identity: PubChem CID 9941957, sequence GEPPPGKPADDAGLV, formula C₆₂H₉₈N₁₆O₂₂ and molecular weight approximately 1419.5 Da. Regulatory context: FDA official July 23–24, 2026 PCAC meeting page and BPC-157 briefing document; advisory review is non-binding and not approval. Anti-doping context: official WADA 2026 Prohibited List, S0. Evidence context includes the 2022 rat/beagle-dog pharmacokinetic study, PMC9794587; preclinical gastrointestinal and tissue-repair literature; toxicology literature; and the 2025 report PMID 40131143 involving only 2 healthy adults. Vendor and community protocols were excluded.
  1. 01

    Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications

    Current Neuropharmacology · 2016 · peer-reviewed review article

    Open source
  2. 02

    Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future

    Gut and Liver · 2020 · peer-reviewed review article

    Open source
  3. 03

    The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

    Journal of Applied Physiology · 2011 · peer-reviewed original research (in vitro/ex vivo tendon explant study)

    Open source
  4. 04

    Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts

    Molecules · 2014 · peer-reviewed original research

    Open source
  5. 05

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    HSS Journal (Hospital for Special Surgery Journal) · 2025 · systematic review

    Open source
  6. 06

    From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management

    International Journal of Molecular Sciences · 2026 · peer-reviewed review article

    Open source
  7. 07

    PCO-02 - Safety and Pharmacokinetics Trial

    ClinicalTrials.gov (U.S. National Library of Medicine trial registry) · 2015 · clinical trial registry entry (Phase I, randomized, placebo-controlled, pilot)

    Open source
  8. 08

    Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks

    U.S. Food and Drug Administration (FDA.gov) · 2026 · regulatory document / federal agency list

    Open source

Product FAQ

Questions buyers ask about BPC-157

What is established about BPC-157 identity and sequence?+

The free peptide is a linear 15-residue sequence, GEPPPGKPADDAGLV, recorded by PubChem CID 9941957 with formula C₆₂H₉₈N₁₆O₂₂ and molecular weight about 1419.5 Da. Identity still requires the offered lot’s terminal state, salt or counterion, theoretical and observed intact mass, sequence evidence and quantitative content. Sequence composition alone does not prove unusual oral, gastric or serum stability.

How should free base and acetate be specified?+

Do not rely on the name BPC-157 alone. The quotation and COA should state free base versus acetate, CAS or registry mapping where applicable, formula and molecular-weight basis, counterion content, water, peptide assay, intact mass, chromatographic method and impurity profile. Activity per gross vial mass cannot be assumed equivalent when salt, water and peptide-content bases differ.

Is co-formulation with TB-500 or other peptides established?+

No controlled peer-reviewed study identified a clinically validated BPC-157/TB-500 combination or universal solution compatibility. Co-lyophilization is a separate formulation-development project requiring identity, ratio, content uniformity, impurity, stability and container-closure evidence for the actual blend. Marketing popularity is not evidence of synergy or stability.

Related research materials

Compare adjacent molecules and documentation needs.

Full catalog
Repair and regenerative research

TB-500

N-acetylated LKKTETQ thymosin-β4 fragment research reference

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request
Repair and regenerative research

BPC-157 + TB-500 (Wolverine Stack)

BPC-157 + Ac-LKKTETQ two-peptide research pairing · no established biological synergy

Purity
Component-specific · Batch COA
CAS
137525-51-0
Latest batch COA available on request
Repair and regenerative research

GHK-Cu

Copper(II)-complexed GHK tripeptide · supplied form and copper stoichiometry are procurement-critical

Purity
Lot-specific · Batch COA
CAS
89030-95-5
Latest batch COA available on request
Repair and regenerative research

TB500 Fragment (Frag 17-23)

N-acetylated thymosin-β4 residues 17–23 research fragment · not full-length thymosin-β4

Purity
Lot-specific · Batch COA
CAS
885340-08-9
Latest batch COA available on request